BRPI0607770A2 - compostos de nucleosideo tricìclico para tratamento de infecções virais - Google Patents

compostos de nucleosideo tricìclico para tratamento de infecções virais

Info

Publication number
BRPI0607770A2
BRPI0607770A2 BRPI0607770-6A BRPI0607770A BRPI0607770A2 BR PI0607770 A2 BRPI0607770 A2 BR PI0607770A2 BR PI0607770 A BRPI0607770 A BR PI0607770A BR PI0607770 A2 BRPI0607770 A2 BR PI0607770A2
Authority
BR
Brazil
Prior art keywords
viral infections
treatment
nucleoside compounds
tricyclic nucleoside
tricyclic
Prior art date
Application number
BRPI0607770-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Jesse D Keicher
Christopher Don Roberts
Sebastian Johannes Reinhard Liehr
Xiaoling Zheng
Marija Prhavc
Vivek Kumar Rajwanshi
Ronald Conrad Griffith
Choung U Kim
Original Assignee
Genelabs Tech Inc
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc, Gilead Sciences Inc filed Critical Genelabs Tech Inc
Publication of BRPI0607770A2 publication Critical patent/BRPI0607770A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22Pteridine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0607770-6A 2005-02-28 2006-02-28 compostos de nucleosideo tricìclico para tratamento de infecções virais BRPI0607770A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65746305P 2005-02-28 2005-02-28
PCT/US2006/007132 WO2006093987A1 (en) 2005-02-28 2006-02-28 Tricyclic-nucleoside compounds for treating viral infections

Publications (1)

Publication Number Publication Date
BRPI0607770A2 true BRPI0607770A2 (pt) 2009-06-13

Family

ID=36570903

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0607770-6A BRPI0607770A2 (pt) 2005-02-28 2006-02-28 compostos de nucleosideo tricìclico para tratamento de infecções virais
BRPI0607769-2A BRPI0607769A2 (pt) 2005-02-28 2006-02-28 pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0607769-2A BRPI0607769A2 (pt) 2005-02-28 2006-02-28 pró-fármacos nucleosìdeo-tricìclicos para tratamento de infecções virais

Country Status (18)

Country Link
US (4) US7534771B2 (OSRAM)
EP (2) EP1853617A1 (OSRAM)
JP (2) JP2008531703A (OSRAM)
KR (2) KR20070106781A (OSRAM)
CN (2) CN101142226A (OSRAM)
AP (2) AP2007004128A0 (OSRAM)
AR (1) AR058419A1 (OSRAM)
AU (2) AU2006218704A1 (OSRAM)
BR (2) BRPI0607770A2 (OSRAM)
CA (2) CA2597683A1 (OSRAM)
EA (2) EA200701850A1 (OSRAM)
HR (2) HRP20070436A2 (OSRAM)
IL (2) IL184955A0 (OSRAM)
MX (2) MX2007010463A (OSRAM)
NO (2) NO20074613L (OSRAM)
TW (1) TW200640474A (OSRAM)
WO (2) WO2006093987A1 (OSRAM)
ZA (1) ZA200707410B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004029904D1 (de) * 2003-08-27 2010-12-16 Biota Scient Management Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
CN101142226A (zh) * 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
PL2144604T3 (pl) 2007-02-28 2012-02-29 Conatus Pharmaceuticals Inc Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
KR101927905B1 (ko) * 2008-04-03 2018-12-11 스프링 뱅크 파마슈티칼스, 인크. 바이러스 감염증을 치료하기 위한 조성물 및 방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8716263B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
GB0900914D0 (en) * 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
CA2756815A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2726610A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
WO2013033093A1 (en) * 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2639238A1 (en) * 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
AR090699A1 (es) * 2012-04-18 2014-12-03 Biocryst Pharm Inc Compuestos inhibidores de la actividad de la arn polimerasa viral
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
BR112015007698A2 (pt) 2012-10-08 2017-08-22 Idenix Pharmaceuticals Inc Centre National De La Recherche Scientifique E Univ Montpellier 2 Science Composto, composição farmacêutica, e, uso de um composto
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5371017A (en) * 1990-04-04 1994-12-06 Chiron Corporation Hepatitis C virus protease
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0693126B9 (en) * 1993-04-02 2007-09-12 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
CA2233309A1 (en) 1995-09-27 1997-04-03 Emory University Recombinant hepatitis c virus rna replicase
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
PL335721A1 (en) * 1997-03-05 2000-05-08 Ribogene Novel methods of screening serving the purpose of identifying the factors of selective hepatitis c virus replication inhibition
EP0973788A1 (en) * 1997-04-02 2000-01-26 Amersham Pharmacia Biotech UK Limited Tricyclic base analogues
JP2001526028A (ja) * 1997-12-11 2001-12-18 スミスクライン・ビーチャム・コーポレイション C型肝炎ウイルスns5b末端切断タンパク質およびその抗ウイルス化合物同定方法
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1267446C (zh) * 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
WO2003061385A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
US7183302B2 (en) 2002-08-12 2007-02-27 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of HCV replication
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
DE602004029904D1 (de) 2003-08-27 2010-12-16 Biota Scient Management Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
US7144868B2 (en) * 2003-10-27 2006-12-05 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2542776A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101142226A (zh) * 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物

Also Published As

Publication number Publication date
MX2007010460A (es) 2007-11-08
US20060194749A1 (en) 2006-08-31
AP2007004128A0 (en) 2007-08-31
JP2008531704A (ja) 2008-08-14
AP2007004118A0 (en) 2007-08-31
IL184954A0 (en) 2007-12-03
CN101128474A (zh) 2008-02-20
US20090253648A1 (en) 2009-10-08
US7524825B2 (en) 2009-04-28
KR20070106767A (ko) 2007-11-05
US20060252715A1 (en) 2006-11-09
AR058419A1 (es) 2008-02-06
US7534771B2 (en) 2009-05-19
HRP20070435A2 (hr) 2008-02-29
EP1853617A1 (en) 2007-11-14
TW200640474A (en) 2006-12-01
EP1853618A1 (en) 2007-11-14
CN101142226A (zh) 2008-03-12
EA200701850A1 (ru) 2008-02-28
JP2008531703A (ja) 2008-08-14
US20090208457A1 (en) 2009-08-20
MX2007010463A (es) 2007-11-08
CA2597683A1 (en) 2006-09-08
CA2597685A1 (en) 2006-09-08
NO20074915L (no) 2007-11-20
WO2006093987A1 (en) 2006-09-08
KR20070106781A (ko) 2007-11-05
NO20074613L (no) 2007-11-27
BRPI0607769A2 (pt) 2009-10-06
ZA200707410B (en) 2008-10-29
IL184955A0 (en) 2007-12-03
HRP20070436A2 (hr) 2008-02-29
HRP20070435A9 (en) 2008-09-30
EA200701849A1 (ru) 2008-02-28
AU2006218704A1 (en) 2006-09-08
AU2006218705A1 (en) 2006-09-08
WO2006093986A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
BRPI0607770A2 (pt) compostos de nucleosideo tricìclico para tratamento de infecções virais
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EP1924593B8 (en) Hcv ns3 protease inhibitors
TW200720285A (en) Nucleoside compounds for treating viral infections
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
WO2006119061A3 (en) Hcv ns3 protease inhibitors
MY164469A (en) Hcv ns3 protease inhibitors
TW200517381A (en) Bicyclic heteroaryl derivatives
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
WO2008051477A3 (en) Hcv ns3 protease inhibitors
BR0305259A (pt) Inibidores de hcv ns5b polimerase
NO20073105L (no) Pyridazinonforbindelser
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses
WO2006104945A3 (en) Hepatitis c therapies
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
TR200402534T4 (tr) Viral enfeksiyonların tedavisinde yararlı oksazinokuinolonlar.
GT200600262A (es) Uso de la sangliferina en el hcv (virus de la hepatitis "c")
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
UA90909C2 (en) Hcv ns3 protease inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GENELABS TECHNOLOGIES, INC. (US)

Free format text: TRANFERIDO DE: GILEAD SCIENCES, INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.